Calibr-Skaggs Administers First Patient with Switchable CAR-T Cell Therapy in Phase 1 Trial Targeting Metastatic Breast Cancer Calibr-Skaggs Administers First Patient with Switchable CAR-T Cell Therapy in Phase 1 Trial Targeting Metastatic Breast Cancer June 17, 2025Posted inBiotechnology nginx Post navigation Previous Post Mabion Launches €500,000 Services Contest to Support Next-Gen Oncology AdvancesNext PostThriving Habitats: The Flourishing World of Wild Bees
